Thursday, July 9, 2026
HomeTagsLantern Pharma

Tag: Lantern Pharma

Healthcare

Lantern Pharma Reveals withZeta.ai Co-Scientist Roadmap

withZeta.ai is now commercially available with a fully enabled subscription payment model serving the full spectrum of the biomedical research and drug development community Lantern...
Healthcare

Lantern Wins EU Patent for AI-Driven Cancer Drug LP-284

Lantern Pharma Inc., a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to accelerate drug discovery, announced that the European Patent...
Healthcare

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Lantern Pharma Inc., an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®,...
Healthcare

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

Lantern Pharma Inc., an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (“ML”) platform...

Recent Published

About Us

Discover the future of artificial intelligence at AITech365. Explore the latest AI news, delve into insightful interviews with industry experts, and stay informed about the most exciting and trending topics shaping the world of AI.

Latest

Popular

Quick Link

© 2026 AITech365. All Rights Reserved. Website Undertaking: Data Demand